Abstract
ABSTRACTThe Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and previously-infected individuals due to its ability to evade neutralization by antibodies. With three sub-lineages of Omicron emerging in the last four months, there is inadequate information on the quantitative antibody response generated upon natural infection with Omicron variant and whether these antibodies offer cross-protection against other sub-lineages of Omicron variant. In this study, we characterized the growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells. Relatively higher amounts infectious virus titers, cytopathic effect and disruption of epithelial barrier functions was observed with Delta variant whereas infection with Omicron variant led to a more robust induction of interferon pathway, lower level of virus replication and mild effect on epithelial barrier. The replication kinetics of BA.1 and BA.2 sub-lineages of the Omicron variant were comparable in cell culture and natural Omicron infection in a subset of individuals led to a significant increase in binding and neutralizing antibodies to both BA.1 and BA.2 sub-lineages but these levels were lower than that produced against the Delta variant. Finally, we show that Cu2+, Zn2+ and Fe2+ salts inhibited in vitro RdRp activity but only Cu2+ and Fe2+ inhibited both the Delta and Omicron variants in cell culture. Thus, our results suggest that high levels of interferons induced upon infection with Omicron variant may counter virus replication and spread. Waning neutralizing antibody titers rendered subjects susceptible to infection by Omicron variant and natural Omicron infection elicits neutralizing antibodies that can cross-react with other sub-lineages of Omicron and other variants of concern.
Publisher
Cold Spring Harbor Laboratory
Reference67 articles.
1. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021;Euro Surveill,2021
2. Fisman DN , Tuite AR . Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv. 2021:2021.07.05.21260050.
3. Li B , Deng A , Li K , Hu Y , Li Z , Xiong Q , et al. Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv. 2021:2021.07.07.21260122.
4. Mlcochova P , Kemp S , Dhar MS , Papa G , Meng B , Mishra S , et al. SARS-CoV-2 Delta variant emergence, replication and sensitivity to neutralising antibodies. bioRxiv. 2021:2021.05.08.443253.
5. Bernal JL , Andrews N , Gower C , Gallagher E , Simmons R , Thelwall S , et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021:2021.05.22.21257658.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献